Pharmafile Logo
Pharmafocus logo
Advanced Search

Neurology

Showing 15 posts of 109 posts found.

EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy

December 10, 2025
Research and Development EpilepsyGTx, Neurology, epilepsy

EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, has announced $33m raised in …

News

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder

December 8, 2025
Research and Development Neurology, UCB, epilepsy

UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can significantly reduce the frequency of …

News

Teva announces positive results from trial of AJOVY for migraine

December 5, 2025
Research and Development Neurology, Teva, migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and …

News

Rare and severe epilepsies – current treatments and advance therapeutics

August 29, 2025
Medical Communications, Research and Development Neurology, UCB, epilepsy, epilepsy treatment, rare epilepsies

The current forms of immunotherapy, how T cell therapy works and what the future holds

Feature
epilepsy-623346_960_720

Epilepsy Research Institute opens 2025-26 grant round with new awards

August 21, 2025
Medical Communications, Research and Development Neurology, epilepsy, funding programme, medical research

The Epilepsy Research Institute has opened its 2025-26 Grant Round, offering a wide range of funding opportunities designed to support …

News

Five Facts about epilepsy

August 21, 2025
Medical Communications Five Facts, Neurology, epilepsy, neurological condition, seizures

1 Epilepsy occurs when the normal electrical activity in the brain changes. For many, the cause is unclear, but genes …

Feature
brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631

FDA decision on Neurizon’s ALS therapy delayed until October

August 18, 2025
Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis

Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the company’s Clinical …

News
Patients image

PhotoPharmics expands Parkinson’s Trial into further US states

August 14, 2025
Research and Development Neurology, PhotoPharmics, clinical trial, neurodegenerative disorders

US-based PhotoPharmics, has expanded enrollment in its Light for PD clinical trial beyond its original 300 participants, opening new sites …

News

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025
Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …

News
sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

August 6, 2025
Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …

News
brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

August 6, 2025
Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …

News
alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

July 30, 2025
Research and Development Alzheimer's disease, CE Mark approval, Eli Lilly, Neurology, Roche

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in vitro diagnostic regulation-certified blood-based diagnostic …

News

Relief Therapeutics to merge with NeuroX to create AI-driven neurohealth company

July 29, 2025
Mergers and Acquisitions, Research and Development AI, Corporate, MindMaze, Neurology, Relief Therapeutics, neurological conditions

Relief Therapeutics has announced that it will combine with NeuroX Group, the successor to digital neurotherapeutics company MindMaze. The transaction …

News

Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate

July 28, 2025
Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis

Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …

Appointment

MetP Pharma releases positive data on intranasal semaglutide administration

July 22, 2025
Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide

MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025